Enlivex Therapeutics (NASDAQ: ENLV) files Q2 2025 financials and review

Rhea-AI Filing Summary

Enlivex Therapeutics Ltd. filed a Form 6-K as a foreign private issuer, furnishing its unaudited condensed consolidated financial statements for the three and six month periods ended June 30, 2025 and 2024. The filing also includes an Operating and Financial Review and Prospects for the same periods, provided as Exhibits 99.1 and 99.2. These materials are incorporated by reference into Enlivex’s existing registration statements on Forms S-8 and F-3, allowing those registration statements to use the latest interim financial and operating information.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: August 2025

Commission file number: 001-36578

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

Financial Statements

The unaudited condensed consolidated financial statements for Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (“Enlivex”), as of and for the three and six month periods ended June 30, 2025 and 2024, and the Operating and Financial Review and Prospects of Enlivex for the corresponding periods are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report on Form 6-K and incorporated by reference into Enlivex’s registration statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799, File No. 333-232413, File No. 333-232009, File No. 333-252926 and File No. 333-286956), filed with the Securities and Exchange Commission.

Exhibit No.
99.1		Unaudited condensed consolidated financial statements for Enlivex as of June 30, 2025 and December 31, 2024 and for the three and six month periods ended June 30, 2025 and 2024.
99.2		Operating and Financial Review and Prospects as of and for the three and six month periods ended June 30, 2025 and 2024.
101.INS		Inline XBRL Instance Document
101.SCH		Inline Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Defeinition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Enlivex Therapeutics Ltd.
	(Registrant)
	By:	/s/ Oren Hershkovitz
	Name:	Oren Hershkovitz
	Title:	Chief Executive Officer

Date: August 29, 2025

2

FAQ

What did Enlivex Therapeutics Ltd. (ENLV) file in this Form 6-K?

Enlivex Therapeutics Ltd. furnished a Form 6-K containing its unaudited condensed consolidated financial statements and an Operating and Financial Review and Prospects for the three and six month periods ended June 30, 2025 and 2024.

Which financial periods are covered in Enlivex (ENLV)'s latest Form 6-K?

The Form 6-K covers Enlivex’s financial information as of June 30, 2025 and December 31, 2024, and results for the three and six month periods ended June 30, 2025 and 2024.

What exhibits are included in Enlivex Therapeutics Ltd. (ENLV)'s Form 6-K?

The filing includes Exhibit 99.1 (unaudited condensed consolidated financial statements) and Exhibit 99.2 (Operating and Financial Review and Prospects), along with related Inline XBRL data files.

How does this Form 6-K affect Enlivex (ENLV)'s existing registration statements?

The financial statements and operating review furnished in this Form 6-K are incorporated by reference into Enlivex’s registration statements on Forms S-8, F-3 and F-3MEF, updating those registrations with the latest interim information.

Who signed Enlivex Therapeutics Ltd. (ENLV)'s Form 6-K?

The Form 6-K was signed on behalf of Enlivex Therapeutics Ltd. by Oren Hershkovitz, who is identified as the Chief Executive Officer.

Is Enlivex Therapeutics Ltd. (ENLV) considered a foreign private issuer in this filing?

Yes. The document is a Form 6-K Report of Foreign Private Issuer filed under the Securities Exchange Act of 1934.